SCHEMBL7144909

SCHEMBL7144909

COc1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
KDM4E B2RXH2 3/20 0.46
HPGD P15428 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 1/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7144725 0.99 ALDH1A1 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7140253 0.90 NPC1 (0.51) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1660430 0.87 KDM4E (0.60) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8118299 0.84 PDGFRB (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8124257 0.82 PDGFRB (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8123906 0.81 PDGFRB (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL17280155 0.81 MEN1 (0.49) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL28003334 0.80 ERN1 (0.45) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL17280154 0.78 PDGFRB (0.45) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL15007490 0.78 MEN1 (0.41) NPC1RAB9AMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed